Enorama Pharma AB (publ) postpones publication of its interim report for the third quarter of 2026
Cision•13/11/2026•08:00 ET
0
Key Highlights
- ➤Q3 2026 interim report postponed from 18 November to 27 November 2026
- ➤Publication delay attributed to administrative reasons
- ➤Enorama Pharma (ERMA) remains listed on Nasdaq First North Growth Market
Enorama Pharma Enorama Pharma AB (publ) ("Enorama" or "the Company") today announces that the board of directors has decided to postpone the publication of the Company's interim report for the third quarter of 2026 from 18 November 2026 to 27 November 2026.
CONTACT Enorama Pharma AB (publ) Amy Walker, acting CEO info@enorama.se Strandvägen 7A, 114 51 Stockholm. www.enorama.se
Get started
Create a free account to read the full story.